---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Mar 22, 2008 at 1:20 PM
Subject: MR imaging of ovarian tumors using folate-receptor-targeted contrast agents.
To: mesothelioma77@gmail.com
[1]Pediatr Radiol. 2008 Mar 21;
Wang ZJ, Boddington S, Wendland M, Meier R, Corot C, Daldrup-Link H
BACKGROUND: Because of its over-expression in many human tumors, the folate receptor (FR) is a promising target for tumor-specific imaging. OBJECTIVE: To evaluate the uptake of FR-targeted gadolinium (P866) and iron-oxide (P1048) agents in an ovarian tumor model. MATERIALS AND METHODS: FR-positive ovarian cancer cells (IGROV-1) were incubated with FR-targeted agents (P866 or P1048) in the absence or presence of competing free folate. Intracellular gadolinium or iron-oxide concentrations were measured. MR imaging of implanted ovarian tumors in rats was performed following injection of FR-targeted (P866 and P1048) and nontargeted (P1001 and P904) agents. Changes in longitudinal and transverse relaxation rates (DeltaR1 and DeltaR2), which were proportional to the contrast agent concentration in the tumors, were compared between tumors injected with FR-targeted and nontargeted agents. RESULTS: IGROV-1 cells showed uptake of P866 and P1048, which decreased with competing free folate. The DeltaR1 values were higher at 1 h following injection of P866 than following injection of P1001 (P
___
Source: http://www.hubmed.org/display.cgi?uids=18357444
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Mar 22, 2008 at 1:20 PM
Subject: MR imaging of ovarian tumors using folate-receptor-targeted contrast agents.
To: mesothelioma77@gmail.com
[1]Pediatr Radiol. 2008 Mar 21;
Wang ZJ, Boddington S, Wendland M, Meier R, Corot C, Daldrup-Link H
BACKGROUND: Because of its over-expression in many human tumors, the folate receptor (FR) is a promising target for tumor-specific imaging. OBJECTIVE: To evaluate the uptake of FR-targeted gadolinium (P866) and iron-oxide (P1048) agents in an ovarian tumor model. MATERIALS AND METHODS: FR-positive ovarian cancer cells (IGROV-1) were incubated with FR-targeted agents (P866 or P1048) in the absence or presence of competing free folate. Intracellular gadolinium or iron-oxide concentrations were measured. MR imaging of implanted ovarian tumors in rats was performed following injection of FR-targeted (P866 and P1048) and nontargeted (P1001 and P904) agents. Changes in longitudinal and transverse relaxation rates (DeltaR1 and DeltaR2), which were proportional to the contrast agent concentration in the tumors, were compared between tumors injected with FR-targeted and nontargeted agents. RESULTS: IGROV-1 cells showed uptake of P866 and P1048, which decreased with competing free folate. The DeltaR1 values were higher at 1 h following injection of P866 than following injection of P1001 (P
___
Source: http://www.hubmed.org/display.cgi?uids=18357444
--
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc